Intradermal Platelet-Rich Plasma for the Treatment of Melasma: A Clinical and Dermoscopic Evaluation in Dark Skin

This study assessed the effectiveness of intradermal platelet-rich plasma (PRP) for treating melasma in 20 female patients with Fitzpatrick skin types IV–V. Over 12 weeks, patients received three PRP treatments, resulting in a significant reduction in melasma severity, as indicated by the modified melasma area and severity score (mMASI). No relapse was observed during a three-month follow-up, and both clinical and dermoscopic evaluations showed improvement. Mild side effects were noted but resolved quickly. The study concluded that PRP could be a viable first-line treatment for melasma in darker skin types, especially when combined with strict sun protection. Despite limitations like a small sample size, PRP was considered a safe and effective option, particularly for mild cases or as an adjunct therapy for more severe cases.